D-1491-2016 Class II Terminated
FDA drug recall D-1491-2016 was initiated by Zydus Pharmaceuticals USA Inc on May 9, 2016 and is designated Class II. Reason for recall: Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two… The recall status is terminated (terminated May 1, 2018). Affected quantity: 14,808 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 14, 2016
- Initiation Date
- May 9, 2016
- Termination Date
- May 1, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 14,808 bottles
Product description
Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06
Reason for recall
Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.
Distribution pattern
US Nationwide
Code information
Lot # MP993, Exp10/16; MR2704, Exp 02/17; MR6851, MR8100; Exp 07/17 and MR1210, Exp 12/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1491-2016
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026